TuHURA Biosciences, Inc./NV (HURA) Form 8-K — May 15, 2026
TuHURA Biosciences (HURA) reported Q1 2026 financial results, highlighting a $50 million credit facility with its largest stockholder that extends its cash runway into 2028. This non-dilutive financing allows the company to fund operations through anticipated top-line data for its lead IFx-2.0 program in Merkel Cell Carcinoma without issuing new equity. The company ended the quarter with $6.3 million in cash and approximately 63.6 million shares outstanding. Operating expenses remained relatively stable, with R&D at $5.2 million and G&A at $2.3 million, resulting in a net operating cash outflow of $4.4 million.
Key figures
- Debt Amount
- 50000000
- Cash Position
- 6300000
- Interest Rate
- 12
- Maturity Date
- 2031-04-21
- Shares Outstanding
- 63600000
- Ga expense q1 2025
- 2000000
- Ga expense q1 2026
- 2300000
- Rd expense q1 2025
- 4600000
- Rd expense q1 2026
- 5200000
- Financing cash flow q1 2026
- 7200000
Price after filing
Close on the filing date to close N calendar days later (from $2.51). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.